32 results about "Tamsulosine" patented technology

Described are nanoparticulate compositions of finasteride, dutasteride, tamsulosin hydrochloride, or a combination thereof. The formulations exhibit unexpectedly prolonged release and can be maintained in a depot for release to a patient for a period of up to six months.

Novel injectable compositions are provided comprising an active agent which is tamsulosin or letrozole or its pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof and one or more pharmaceutically acceptable excipient(s) wherein the compositions are preferably formulated as biodegradable microparticles or nanoparticles which can optionally be reconstituted with an aqueous, hydro-alcoholic or oily liquid vehicle prior to administration. The novel injectable compositions of the present invention preferably form a depot upon administration in vivo and are in the form of an in situ gelling composition or an implant composition which provides a prolonged release of tamsulosin or letrozole for extended periods of time. Also described are process for preparation of such novel compositions and method of using them.

In an aspect of the invention, a composition for making a patch for the transdermal delivery of tamsulosin is provided. The composition comprises (a) at least about 1 wt % tamsulosin or a pharmaceutically acceptable salt of tamsulosin, (b) at least about 40 wt % polyisobutylene adhesive or hydrophobic synthetic rubber adhesive, (c) about 1-20 wt % of an aprotic solvent in which tamsulosin dissolves readily, (d) about 1-20 wt % of an unsaturated fatty acid or an alpha-hydroxy acid or a mixture of unsaturated fatty acids or alpha-hydroxy acids or of both unsaturated fatty acids and alpha-hydroxy acids, (e) a lipophilic permeation enhancer, and (f) a matrix modifier.

The present invention discloses a method of preparing tamsulosin hydrochloride and subsequent purification by thermal crystallization to provide substantially pure tamsulosin hydrochloride.

The present invention relates to pharmaceutical tablets comprising low amounts of tamsulosim. The invention further relates to the manufacturing process and the therapeutic use of these compounds for the treatment of bening prostatic hyperplasia.

A process for preparing optically pure enantiomers of R-(-)tamsulosin of formiula Ia and S-(+)tamsulosin of formula Ib by resolving racemic tamsulosin of formula I by means of (IR)-(-)-camphor-10-sulfonic acid and (1S)-(+)-camphor-10-sulfonic acid, resp., in an environment of organic solvents, water or mixtures thereof. ##STR00001##

The invention relates to a slow / controlled-release preparation of tamsulosin hydrochloride and a preparation method thereof. The slow / controlled-release preparation comprises (i) a pill core which ismade of the following raw material in parts by weight: 135-165 parts of a microcrystal cellulose micro-pill cores; (ii) a slow-release layer which is made of the following raw materials in parts by weight: 0.36-0.44 parts of tamsulosin hydrochloride, 145-200 parts of a slow / controlled release material and 3.8-58 parts of a pore forming agent. Dissolution degree tests show that the slow / controlled-release tamsulosin hydrochloride preparation consisting of a blank pill core and a medicine-carrying slow / controlled release coating layer has a slow-release effect within a relatively pH value range(the pH value is 1.2, 4 or 6.8), has a pH value independent slow-release property, and is capable of solving the problem that absorption of tamsulosin hydrochloride is affected as the pH value of a gastrointestinal tract is changed if a patient takes foods, therefore, the slow / controlled-release preparation of the tamsulosin hydrochloride, which is provided by the invention, can be taken both before or after a meal, and is relatively convenient to take, and absorption of the tamsulosin hydrochloride is not affected.

The invention discloses a tamsulosin hydrochloride slow-release granule. The slow-release granule uses a blank ball core as a ball core, and sprays a medicine coating layer, an enteric coating layer and a slow-release coating layer on the outside of the ball core in sequence; The layer is obtained by spraying the aqueous solution of tamsulosin hydrochloride and binder; the enteric coating layer is obtained by spraying the enteric coating solution containing enteric materials, plasticizers and anti-adhesive agents; It is obtained by spraying the sustained-release coating solution of insoluble sustained-release materials, plasticizers and anti-sticking agents. In the tamsulosin hydrochloride slow-release microparticles of the present invention, not only the absorption or bioavailability of tamsulosin is not affected by food effects and physiological changes of the gastrointestinal tract before and after meals, but also a stable blood drug concentration curve can be obtained And long-term action time, reduce the occurrence of cardiovascular side effects, greatly improve the safety, effectiveness and compliance of patients taking medicine.

The present invention provides a sustained-release pharmaceutical composition, characterized in that, there are contained tamsulosin or a pharmaceutically acceptable salt thereof and a carrier for a sustained-release pharmaceutical composition and the ratio (Cmin / Cmax ratio) of the plasma tamsulosin concentration at 24 hours after the administration of the preparation per os (Cmin) to the maximum plasma tamsulosin concentration after the administration (Cmax) is about 0.4 or more.

The invention provides a tamsulosin sustained-release pellet, comprising a pill core and a sustained-release coating layer, the sustained-release coating layer comprising a hydrophobic matrix and a pH-sensitive hydrophilic polymer, the polymer polymerized The pH value of the change in solubility of the substance is between 1 and 14, so that the drug can be released at different pH values, and it can also be used as a carrier for controlling the release of tamsulosin, which simplifies the prescription, reduces the difficulty of preparation, and is easier for industrial mass production. The inventors have surprisingly found that the formulation can be used to prepare various sustained-release dosage forms of tamsulosin, independent of the physicochemical properties of tamsulosin.